Abstract: This invention provides a medical device for delivering volumetric quantities of a first and a second biochemically reactive fluid in which separate MBUs atomize the fluids. The device of the present invention includes a fluid delivery device for laparoscopically delivering fluids having two feed conduits for delivering fluid to feed ports of the mechanical breakup units, the mechanical breakup units having two feed ports for receiving fluid from the feed conduits and directing such fluid into spin chambers and funneling portions having a sloped sidewall for directing fluid from the spin chambers through an exit port. The device is suitably dimensioned for creating a spray of two fluids with different viscosities such as fibrinogen and thrombin in such a manner that the thrombin spray cone encompasses the fibrinogen spray cone at a distance of about one inch from the exit port with a 0.5 cc/second flow rate to avoid depositing unreacted fibrinogen on a surface.

Abstract: This invention provides a medical device for delivering volumetric quantities of a first and a second biochemically reactive fluid comprising a first container having an opening, the first container being adapted to contain the first biochemically reactive fluid; a second container having a second fluid opening adjacent the first fluid opening, the second container being adapted to contain the second biochemically reactive fluid; a spray unit for separately atomizing the first and second biochemically reactive fluids into an aerosol with at least one energy source of a liquid energy, a mechanical energy, a vibration energy, and an electric energy; a fluid pressurizer for pressurizing the first and the second biochemically reactive fluids for delivery under pressure through the spray unit onto a surface; and wherein the first and second biochemically reactive fluids first mix on the surface.

Abstract: This invention provides a medical device for delivering volumetric quantities of a first and a second biochemically reactive fluid comprising a first container having an opening, the first container being adapted to contain the first biochemically reactive fluid; a second container having a second fluid opening adjacent the first fluid opening, the second container being adapted to contain the second biochemically reactive fluid; a spray unit for separately atomizing the first and second biochemically reactive fluids into an aerosol with at least one energy source of a liquid energy, a mechanical energy, a vibration energy, and an electric energy; a fluid pressurizer for pressurizing the first and the second biochemically reactive fluids for delivery under pressure through the spray unit onto a surface; and wherein the first and second biochemically reactive fluids first mix on the surface.

Abstract: A process for the separation and isolation of AHF, fibronectin and von Willebrand's ristocetin cofactor from blood plasma by adding a sulfated mucopolysaccharide to blood plasma to a concentration of from about 0.05 to about 0.4 mg/ml of plasma, cooling the plasma to 0.degree. C.-15.degree. C., centrifuging the plasma to isolate a precipitate which forms and then removing the AHF-rich supernatant liquid from the precipitate.The precipitate is washed in a slightly basic solution of dilute salts and then dissolved in a buffered solution of chaotrophic salts of the Hofmeister series having an ionic strength from 0.01-1. Fibronectin is separated by chromotographic means from the dissolved precipitate which contains fibronectin and fibrinogen.The dissolved precipitate may also be applied to a glass or plastic column containing a 4% agarose gel (E. G. Sepharose 4B or Biogel A-15m) in a 0.25 molar solution sodium phosphate titrated to pH 7.0 with any base, preferably TRIS.

Abstract: A process for the separation and isolation of AHF and fibronectin from blood plasma by adding a sulfated mucopolysaccharide to blood plasma to a concentration of 0.15-0.25 mg/ml of plasma, cooling the plasma to 0.degree. C.-15.degree. C. centrifuging the plasma to isolate a precipitate which forms and then removing the AHF-rich supernatant liquid from the precipitate.The precipitate is washed in a slightly basic solution of dilute salts and then dissolved in a buffered solution of chaotrophic salts of the Hofmeister series having an ionic strength from 0.01-1. Fibronectin is then separated, by chromotographic means, from the dissolved precipitate, which contains fibronectin and fibrinogen.In a preferred embodiment, 0.20 mg of sodium heparin per milliliter of human plasma is employed with the heparinized plasma solution cooled for 3 hours at a temperature of 2.degree. C.-4.degree. C.